Alfa Thermodiagnostics, Inc. has engineered a next-generation Whole-Body Thermometry adjunct diagnostic tool that provides a visible measurement of the Autonomic Nervous System, often the key to the causal factors of many diseases. The AlfaSight 9000™ is grounded in the established science of Regulation Thermography which was invented and first commercialized in Germany more than 20 years ago. It is a proven, accurate technology supported by more than 100,000 patient assessments, and has been clinically correlated with hundreds of MRI & CT Scans.

Dr. Daniel Beilin led the US FDA clearance of first-generation Regulation Thermography technology in 1996 and has now successfully led Alfa’s Infared upgraded system to once again receive FDA 510k marketing status as an adjunct diagnostic device. He is recognized worldwide as the foremost authority on Whole-Body Thermometry, and is supported by leaders in the fields of Radiology, Neurobiology, and Regulation Medicine.

The AlfaSight 9000™ is a non-invasive patient assessment tool that identifies a wide range of physiological dysfunction by analyzing skin temperature changes over time. As an adjunct technology to mammography and other anatomical imaging devices, it can dramatically improve the accuracy of routine screening for a wide range of impaired health conditions.

Product Availability

The AlfaSight 9000™ has obtained FDA 510(k) clearance, CE marking and Health Canada licensing and is available for purchase in the United States, Europe Economic Area (EEA) countries, Canada, and Asian Markets.